In Part II, we take a personal look at the journey into PTSD Hell. We also examine the additional serious issues facing veterans attempting to cope with PTSD.
In Part II, we take a personal look at the journey into PTSD Hell. We also examine the additional serious issues facing veterans attempting to cope with PTSD.
2021 was two different "years" for the psychedelic drug industry. Impressive progress in drug R&D and clinics; stocks pushed down to absurdly lean multiples.
MINDCURE moves an important step closer to the full commercial deployment of its iSTRYM digital therapeutics platform, and also makes a key addition to its management team.
The ongoing and worsening mental health crisis in the U.S. military is a national tragedy and a national disgrace. Part I reveals the ugly Big Picture.
MINDCURE's iSTRYM digital therapeutics platform is a first-mover in supplying this critical IT to mental health treatment. But that's only the beginning of its potential.
GH Research just released outstanding clinical results for its psychedelic-assisted therapy for TRD. Markets badly mis-pricing these stocks at present.
Psychedelic stocks have recently been punished by the market. The flip-side is that many well-capitalized companies now offer spectacular value propositions.
Digital therapeutics is the key to the rapid commercialization of psychedelic medicine. MINDCURE's iSTRYM digital therapeutics platform is the first-mover in the industry.
Psychedelic medicine is both extremely efficacious and highly cost-effective. It is also an absolute necessity to RESCUE the economy.
Compass Pathways surprised and disappointed the market with its Phase IIb clinical results. Despite the immediate overall selloff on the news, the outlook for many psychedelic stocks is now BETTER.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now